Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

Journal of Clinical Oncology

Volumn 26, Issue 11, 2008, Pages 1810-1816

  Burstein, Harold J ^a   Elias, Anthony D ^a   Rugo, Hope S ^a   Cobleigh, Melody A ^a   Wolff, Antonio C ^a   Eisenberg, Peter D ^a   Lehman, Mary ^a   Adams, Bonne J ^a   Bello, Carlo L ^a   DePrimo, Samuel E ^a   Baum, Charles M ^a   Miller, Kathy D ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; STEM CELL FACTOR RECEPTOR; SU 12662; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; INDOLE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRROLE DERIVATIVE; TAXANE; TAXOID; TUMOR MARKER;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFUSION; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EPISTAXIS; EXTREMITY PAIN; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPERURICEMIA; INSOMNIA; LEUKOCYTE; LEUKOPENIA; MAJOR CLINICAL STUDY; MONOTHERAPY; MORNING DOSAGE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN DISCOLORATION; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; BLOOD; BREAST TUMOR; CARCINOMA; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; DRUG ADMINISTRATION; DRUG ANTAGONISM; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; METASTASIS; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; SURVIVAL RATE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CARCINOMA; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; INDOLES; MIDDLE AGED; PROTEIN-TYROSINE KINASES; PYRROLES; SURVIVAL RATE; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 42949148257     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.5375     Document Type: Article

References (32)

1. Gasparini G: Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 5:37-44, 2000 (suppl 1)
2. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6, 1990
3. Relf M, LeJeune S, Scott PA, et al: Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963-969, 1997
4. Yoshiji H, Gomez DE, Shibuya M, et al: Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 56:2013-2016, 1996
5. Price DJ, Miralem T, Jiang S, et al: Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 12:129-135, 2001
6. Nakopoulou L, Stefanaki K, Panayotopoulou E, et al: Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: Correlation with proliferation. Hum Pathol 33:863-870, 2002
7. Kranz A, Mattfeldt T, Waltenberger J: Molecular mediators of tumor angiogenesis: Enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Int J Cancer 84:293-298, 1999
8. Rosen LS: VEGF-targeted therapy: Therapeutic potential and recent advances. Oncologist 10:382-391, 2005
9. de Jong JS, van Diest PJ, van der Valk P, et al: Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops. J Pathol 184:44-52, 1998
10. Bhardwaj B, Klassen J, Cossette N, et al: Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma. Clin Cancer Res 2:773-782, 1996
11. Ariad S, Seymour L, Bezwoda WR: Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: Correlation with stage and rate of progression. Breast Cancer Res Treat 20:11-17, 1991
12. Seymour L, Dajee D, Bezwoda WR: Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat 26:247-252, 1993
13. Carvalho S, e Silva AO, Milanezi F, et al: C-KIT and PDGFRA in breast phyllodes tumours: Overexpression without mutations? J Clin Pathol 57:1075-1079, 2004
14. Goswami S, Sahai E, Wyckoff JB, et al: Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res 65:5278-5283, 2005
15. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
16. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003
17. Abrams TJ, Lee LB, Murray LJ, et al: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478, 2003
18. Murray LJ, Abrams TJ, Long KR, et al: SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757-766, 2003
19. Abrams TJ, Murray LJ, Pesenti E, et al: Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2:1011-1021, 2003
20. Raymond E, Faivre S, Vera K, et al: Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers. Proc Am Soc Clin Oncol 22:192, 2003 (abstr 769)
21. Rosen L, Mulay M, Long J, et al: Phase I trial of SU11248, a novel tyrosine kinase inhibitor in advanced solid tumors. Proc Am Soc Clin Oncol 22:191, 2003 (abstr 765)
22. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
23. Bello CL, Sherman L, Zhou J, et al: Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: Results from a phase I study in healthy subjects. Anticancer Drugs 17:353-358, 2006
24. DePrimo SE, Friece C, Huang X: Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer. J Clin Oncol 24:22s, 2006 (abstr 578)
25. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007
26. Demetri DG, van Oosterom A, Garrett CR, et al: Efficacy and safety of sunitinib malate in patients with advanced gastrointestinal stromal tumor following failure of imatinib mesylate due to resistance or intolerance. Lancet 368:1329-1338, 2006
27. DePrimo SE, Bello CL, Smeraglia J, et al: Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: Modulation of VEGF and VEGF-related proteins. J Trans Med 5:32, 2007
28. Motzer RJ, Michaelson MD, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24, 2006
29. Srinivas S, Roigas J, Gillessen S, et al: Continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma: Updated results. J Clin Oncol 25:244s, 2007 (abstr 5040)
30. George S, Blay JY, Casali PG, et al: Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in pts with advanced GIST. J Clin Oncol 25:548s, 2007 (abstr 10015)
31. Cobleigh MA, Langmuir VK, Sledge GW, et al: A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30:117-124, 2003
32. Bianchi G, Loibl S, Zamagni C, et al: A phase II, multicentre, uncontrolled trial of sorafenib (BAY 43-9006) in patients with metastatic breast cancer. Eur J Cancer 3:78, 2005 (suppl; abstr 276)